carbonic anhydrase inhibitor
Jump to navigation
Jump to search
Introduction
Carbonic anhydrase inhibitors were developed from testing of sulfonamides for ability to inhibit carbonic anhydrase after it was found that sulfanilamide inhibited carbonic anhydrase.
Monitor
- serum electrolytes every 6 months
- complete blood count (CBC) every 6 months
Adverse effects
- drug adverse effects of diuretics
- drug adverse effects of carbonic anhydrase inhibitor(s)
- drug adverse effects of antihypertensive agents
Notes
- inhibition of mitochondrial carbonic anhydrase suggested to have benefit for aging & neurodegenerative disease[2]
More general terms
More specific terms
- acetazolamide (Diamox)
- brinzolamide (Azopt)
- dichlorphenamide (Daranide)
- dorzolamide (Trusopt)
- methazolamide (Neptazane)
- sulfanilamide
- sulthiame; trolone; sulphenyltame; sulthiamine; (Ospolot)
- topiramate (Topamax, Qudexy XR, Trokendi XR)
Additional terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996 pg 691
- ↑ 2.0 2.1 University of Nottingham. Oct 10, 2016 Cell protein offers new hope in fighting the effects of aging. https://www.nottingham.ac.uk/news/pressreleases/2016/october/cell-protein-offers-new-hope-in-fighting-the-effects-of-aging.aspx
- ↑ Yang MS, Lee JY, Kim J et al Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol Pract 2020 Feb; 8:690 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31614216 https://www.sciencedirect.com/science/article/abs/pii/S221321981930858X
- ↑ 4.0 4.1 4.2 Popovic MM, Schlenker MB, Thiruchelvam D et al Serious Adverse Events of Oral and Topical Carbonic Anhydrase Inhibitors. JAMA Ophthalmol. 2022;140(3):235-242 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35084437 PMCID: PMC8796060 (available on 2023-01-27) https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2788394